Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Recent executive-level company changes and promotions in the biopharma, medical device, and diagnostics industries.

Both AcelRx and Sagent turn to interim CEOs during company transitions.

The biotech has a three-pronged strategy to double revenues by 2017: continue to expand core multiple myeloma product Revlimid, bring new blockbusters online, and develop its early stage pipeline through deals.